Dose-adjusted EPOCH with or without rituximab for aggressive lymphoma patients: real world data.
Adolescent
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Communicable Diseases
/ epidemiology
Cyclophosphamide
/ administration & dosage
Doxorubicin
/ administration & dosage
Etoposide
/ administration & dosage
Feasibility Studies
Febrile Neutropenia
/ epidemiology
Female
Granulocyte Colony-Stimulating Factor
/ administration & dosage
Humans
Lymphoma
/ drug therapy
Male
Middle Aged
Multicenter Studies as Topic
Prednisone
/ administration & dosage
Retrospective Studies
Rituximab
/ administration & dosage
Severity of Illness Index
Treatment Outcome
Vincristine
/ administration & dosage
Young Adult
DA-EPOCH
DLBCL
Lymphoma
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
Dec 2020
Dec 2020
Historique:
received:
11
03
2020
accepted:
25
08
2020
revised:
11
08
2020
pubmed:
4
9
2020
medline:
26
11
2020
entrez:
4
9
2020
Statut:
ppublish
Résumé
CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) -/+ rituximab (R) is the standard chemotherapeutic regimen for aggressive lymphoma, but is insufficient for aggressive lymphoma with adverse prognostic factors. Dose-adjusted (DA)-EPOCH (etoposide, doxorubicin, cyclophosphamide, vincristine, and prednisolone) -/+ R demonstrates excellent efficacy against some aggressive lymphoma. Thus, we conducted a retrospective study to evaluate the feasibility and efficacy of this therapy in clinical practice. We enrolled 149 patients from 17 institutions diagnosed between 2007 and 2015. The median follow-up period for survivors was 27 months (range 0.2-123). The complete response (CR) rate of newly diagnosed patients was 79% (95% CI 68-87%). All patients were hospitalized to receive this therapy and 94% of patients also received granulocyte-colony-stimulating factor support. There were no treatment-related deaths. Febrile neutropenia (FN) and grade 3 or 4 infection occurred in 55% and 28% of patients, respectively. There were no significant differences in FN or infection between young (≤ 65 years) and elderly patients (> 65 years). In newly diagnosed diffuse large B-cell lymphoma-not otherwise specified patients (n = 46), the CR rate was 80% (95% CI 64-91%) and the 2-year OS rate was 81% (95% CI 66-90%). In the present study, DA-EPOCH -/+ R exhibited excellent efficacy and feasibility for aggressive lymphoma.
Identifiants
pubmed: 32880824
doi: 10.1007/s12185-020-02984-w
pii: 10.1007/s12185-020-02984-w
doi:
Substances chimiques
Granulocyte Colony-Stimulating Factor
143011-72-7
Rituximab
4F4X42SYQ6
Vincristine
5J49Q6B70F
Etoposide
6PLQ3CP4P3
Doxorubicin
80168379AG
Cyclophosphamide
8N3DW7272P
Prednisone
VB0R961HZT
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
807-816Subventions
Organisme : Japan Agency for Medical Research and Development (JP)
ID : JP18ck0106439, J.S.
Références
McKelvey EM, Gottlieb JA, Wilson HE, Haut A, Talley RW, Stephens R, et al. Hydroxyldaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. Cancer. 1976;38:1484–93.
doi: 10.1002/1097-0142(197610)38:4<1484::AID-CNCR2820380407>3.0.CO;2-I
Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235–42.
doi: 10.1056/NEJMoa011795
Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood. 2014;123:837–42.
doi: 10.1182/blood-2013-09-524108
Gutierrez M, Chabner BA, Pearson D, Steinberg SM, Jaffe ES, Cheson BD, et al. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol. 2000;18:3633–42.
doi: 10.1200/JCO.2000.18.21.3633
Lai GM, Chen YN, Mickley LA, Fojo AT, Bates SE. P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer. 1991;49:696–703.
doi: 10.1002/ijc.2910490512
Wilson WH, Bates SE, Fojo A, Bryant G, Zhan Z, Regis J, et al. Controlled trial of dexverapamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol. 1995;13:1995–2004.
doi: 10.1200/JCO.1995.13.8.1995
Wilson WH, Grossbard ML, Pittaluga S, Cole D, Pearson D, Drbohlav N, et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood. 2002;99:2685–93.
doi: 10.1182/blood.V99.8.2685
Dunleavy K, Pittaluga S, Maeda LS, Advani R, Chen CC, Hessler J, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;368:1408–16.
doi: 10.1056/NEJMoa1214561
Pinnix CC, Dabaja B, Ahmed MA, Chuang HH, Costelloe C, Wogan CF, et al. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys. 2015;92:113–21.
doi: 10.1016/j.ijrobp.2015.02.006
Binkley MS, Hiniker SM, Wu S, Natkunam Y, Mittra ES, Advani RH, et al. A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy. Leuk Lymphoma. 2016;57:604–8.
doi: 10.3109/10428194.2015.1067700
Giulino-Roth L, O'Donohue T, Chen Z, Bartlett NL, LaCasce A, Martin-Doyle W, et al. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R. Br J Haematol. 2017;179:739–47.
doi: 10.1111/bjh.14951
Dunleavy K, Pittaluga S, Shovlin M, Steinberg SM, Cole D, Grant C, et al. Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med. 2013;369:1915–25.
doi: 10.1056/NEJMoa1308392
Maeda Y, Nishimori H, Yoshida I, Hiramatsu Y, Uno M, Masaki Y, et al. Dose-adjusted EPOCH chemotherapy for untreated peripheral T-cell lymphomas: a multicenter phase II trial of West-JHOG PTCL0707. Haematologica. 2017;102:2097–103.
doi: 10.3324/haematol.2017.167742
Dunleavy K, Pittaluga S, Shovlin M, Roschewski M, Lai C, Steinberg SM, et al. Phase II trial of dose-adjusted EPOCH in untreated systemic anaplastic large cell lymphoma. Haematologica. 2016;101:e27–e2929.
doi: 10.3324/haematol.2015.131151
Wilson WH, Dunleavy K, Pittaluga S, Hegde U, Grant N, Steinberg SM, et al. Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers. J Clin Oncol. 2008;26:2717–24.
doi: 10.1200/JCO.2007.13.1391
Dunleavy K, Little RF, Pittaluga S, Grant N, Wayne AS, Carrasquillo JA, et al. The role of tumor histogenesis, FDG-PET, and short-course EPOCH with dose-dense rituximab (SC-EPOCH-RR) in HIV-associated diffuse large B-cell lymphoma. Blood. 2010;115:3017–24.
doi: 10.1182/blood-2009-11-253039
Sparano JA, Lee JY, Kaplan LD, Levine AM, Ramos JC, Ambinder RF, et al. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood. 2010;115:3008–166.
doi: 10.1182/blood-2009-08-231613
Miyazaki K, Asano N, Yamada T, Takasaki H, Igarashi T, Nishikori M, et al. Dose-adjusted (DA)—EPOCH-R with high-dose methotrexate for newly diagnosed CD5-positive diffuse large B-cell lymphoma (CD5+DLBCL): interim results from a phase II study. Blood. 2016;128:2.
doi: 10.1182/blood.V128.22.2.2
Miyazaki K, Asano N, Yamada T, Miyawaki K, Sakai R, Igarashi T, et al. DA-EPOCH-R combined with high-dose methotrexate in patients with newly diagnosed stage II–IV CD5-positive diffuse large B-cell lymphoma: a single-arm, open-label, phase 2 study. Haematologica. 2019.
Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, et al. Dose-adjusted EPOCH-R compared with R-CHOP as frontline therapy for diffuse large B-cell lymphoma: clinical outcomes of the phase III intergroup trial alliance/CALGB 50303. J Clin Oncol. 2019:JCO1801994.
Yamaguchi M, Nakamura N, Suzuki R, Kagami Y, Okamoto M, Ichinohasama R, et al. De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients. Haematologica. 2008;93:1195–202.
doi: 10.3324/haematol.12810
Ennishi D, Takeuchi K, Yokoyama M, Asai H, Mishima Y, Terui Y, et al. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann Oncol. 2008;19:1921–6.
doi: 10.1093/annonc/mdn392
Zhang XY, Liang JH, Wang L, Zhu HY, Wu W, Cao L, et al. DA-EPOCH-R improves the outcome over that of R-CHOP regimen for DLBCL patients below 60 years, GCB phenotype, and those with high-risk IPI, but not for double expressor lymphoma. J Cancer Res Clin Oncol. 2019;145:117–27.
doi: 10.1007/s00432-018-2771-9
Dunleavy K, Fanale MA, Abramson JS, Noy A, Caimi PF, Pittaluga S, et al. Dose-adjusted EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) in untreated aggressive diffuse large B-cell lymphoma with MYC rearrangement: a prospective, multicentre, single-arm phase 2 study. Lancet Haematol. 2018;5:e609–e617617.
doi: 10.1016/S2352-3026(18)30177-7
Shah NN, Szabo A, Huntington SF, Epperla N, Reddy N, Ganguly S, et al. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis. Br J Haematol. 2018;180:534–44.
doi: 10.1111/bjh.15051
Malenda A, Kolkowska-Lesniak A, Pula B, Dlugosz-Danecka M, Chelstowska M, Konska A, et al. Outcomes of treatment with dose-adjusted EPOCH-R or R-CHOP in primary mediastinal large B-cell lymphoma. Eur J Haematol. 2020;104:59–66.
doi: 10.1111/ejh.13337
Fields PA, Linch DC. Treatment of the elderly patient with diffuse large B cell lymphoma. Br J Haematol. 2012;157:159–70.
doi: 10.1111/j.1365-2141.2011.09011.x
Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23:4117–266.
doi: 10.1200/JCO.2005.09.131
Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile JF, Castaigne S, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2011;12:460–8.
doi: 10.1016/S1470-2045(11)70069-9
Zhang WH, Li GY, Ma YJ, Li ZC, Zhu Y, Chang J, et al. Reduced-dose EPOCH-R chemotherapy for elderly patients with advanced stage diffuse large B cell lymphoma. Ann Hematol. 2018.
Wilson WH, Jung SH, Porcu P, Hurd D, Johnson J, Martin SE, et al. A cancer and leukemia group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica. 2012;97:758–65.
doi: 10.3324/haematol.2011.056531
David RJ, Baran A, Loh KP, Casulo C, Barr PM, Friedberg JW, et al. Complications associated with dose-adjusted EPOCH-rituximab therapy for non-hodgkin lymphoma. Clin Lymphoma Myeloma Leuk. 2018;18:781–7.
doi: 10.1016/j.clml.2018.08.014
Benotti JR, Dalen JE. The natural history of pulmonary embolism. Clin Chest Med. 1984;5:403–10.
pubmed: 6488744
Sakuma M, Nakamura M, Yamada N, Ota S, Shirato K, Nakano T, et al. Venous thromboembolism: deep vein thrombosis with pulmonary embolism, deep vein thrombosis alone, and pulmonary embolism alone. Circ J. 2009;73:305–9.
doi: 10.1253/circj.CJ-08-0372
Linschoten M, Kamphuis JAM, van Rhenen A, Bosman LP, Cramer MJ, Doevendans PA, et al. Cardiovascular adverse events in patients with non-Hodgkin lymphoma treated with first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or CHOP with rituximab (R-CHOP): a systematic review and meta-analysis. Lancet Haematol. 2020;7:e295–e308.
doi: 10.1016/S2352-3026(20)30031-4
Lee YM. To reduce the average length of stay of patients who are admitted for DA-EPOCH-R chemotherapy regimen. BMJ Qual Improv Rep. 2015;4:2.
doi: 10.1136/bmjquality.u208379.w3434
Pejsa V, Prka Z, Lucijanic M, Mitrovic Z, Pirsic M, Jaksic O, et al. Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients. Croat Med J. 2017;58:40–8.
doi: 10.3325/cmj.2017.58.40